Potassium binding polymers for treating hypertension and hyperkalemia
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Oct 27, 2020
Grant Date -
Apr 17, 2014
app pub date -
Oct 8, 2013
filing date -
Oct 8, 2012
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present invention generally relates to methods of treating hypertension (HTN) in patients in need thereof wherein the patient optionally further suffers from chronic kidney disease (CKD) or Type II diabetes mellitus (T2DM). The invention also relates to methods of treating hyperkalemia in a patient in need thereof, wherein the patient suffers from CKD, T2DM or HTN and are optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (RAAS) agent. The invention also relates to methods of treating kidney disease in a patient in need thereof, wherein the patient is optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (RAAS) agent. The methods can comprise administering an effective amount of a potassium-binding polymer to the patient to lower the patient's blood pressure and/or increase or stabilize the patient's kidney function.
First Claim
Other Claims data not available
Family
International Classification(s)
- 2013 Application Filing Year
- A61K Class
- 12711 Applications Filed
- 11051 Patents Issued To-Date
- 86.95 % Issued To-Date
Cited Art Landscape
Patent Citation Ranking
- 0 Citation Count
- A61K Class
- 0 % this patent is cited more than
- 5 Age
Maintenance Fees
| Fee | Large entity fee | small entity fee | micro entity fee | due date |
|---|---|---|---|---|
| 7.5 Year Payment | $3600.00 | $1800.00 | $900.00 | Apr 27, 2028 |
| 11.5 Year Payment | $7400.00 | $3700.00 | $1850.00 | Apr 27, 2032 |
